SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+35.99%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.46B
AUM Growth
+$1.46B
(+38%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
8.68%
Top 10 Holdings %
Top 10 Hldgs %
62.29%
Holding
88
New
21
Increased
19
Reduced
9
Closed
13
Top Buys
| 1 |
AKUS
Akouos, Inc. Common Stock
AKUS
|
$34.1M |
| 2 |
Gilead Sciences
GILD
|
$31M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$26.9M |
| 4 |
Eli Lilly
LLY
|
$24.4M |
| 5 |
AbbVie
ABBV
|
$19.8M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$27.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$21.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$20.4M |
| 4 |
Biogen
BIIB
|
$16.7M |
| 5 |
Merus
MRUS
|
$10.5M |
Sector Composition
| 1 | Healthcare | 98.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $210M | 13.25% | 1,885,602 | – | – |
|
2
Ascendis Pharma
ASND
$11.8B
| $164M | 10.35% | 1,109,874 | – | – |
|
3
Natera
NTRA
$23.1B
| $155M | 9.75% | 3,100,560 | – | – |
|
4
Y-mAbs Therapeutics
YMAB
$388M
| $94.8M | 5.98% | 2,194,278 | – | – |
|
|
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $84.7M | 5.34% | 1,417,258 | – | – |
|
6
NextCure
NXTC
$13.5M
| $57.3M | 3.61% | 2,671,856 | – | – |
|
7
United Therapeutics
UTHR
$13.8B
| $36.9M | 2.32% | 304,562 +71,003 | +30% | +$8.59M |
|
|
AMRN
8
Amarin Corp
AMRN
$311M
| $36M | 2.27% | 5,208,305 | – | – |
|
9
Merck
MRK
$210B
| $34.9M | 2.2% | 451,178 -12,617 | -3% | -$976K |
|
10
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $34.5M | 2.18% | 1,933,221 | – | – |
|
|
AKUS
11
DELISTED
Akouos, Inc. Common Stock
AKUS
| $34.1M | 2.15% | +1,515,073 | New | +$34.1M |
|
|
12
Gilead Sciences
GILD
$140B
| $31M | 1.96% | +403,494 | New | +$31M |
|
|
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $28M | 1.76% | 4,749,623 | – | – |
|
|
14
Jazz Pharmaceuticals
JAZZ
$7.75B
| $26.9M | 1.69% | +243,353 | New | +$26.9M |
|
|
15
AbbVie
ABBV
$372B
| $24.7M | 1.56% | 251,959 +201,959 | +404% | +$19.8M |
|
|
16
Eli Lilly
LLY
$657B
| $24.4M | 1.54% | +148,900 | New | +$24.4M |
|
17
PTC Therapeutics
PTCT
$3.92B
| $22.2M | 1.4% | 438,270 +146,053 | +50% | +$7.41M |
|
|
GRTX
18
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $22M | 1.39% | 3,083,712 | – | – |
|
|
19
Merus
MRUS
$4.98B
| $21.1M | 1.33% | 1,311,039 -650,000 | -33% | -$10.5M |
|
|
XLRN
20
DELISTED
Acceleron Pharma Inc.
XLRN
| $20.7M | 1.31% | 217,390 +52,230 | +32% | +$4.98M |
|
21
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $20.6M | 1.3% | 809,803 -112,897 | -12% | -$2.88M |
|
|
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.1M | 0.89% | +252,958 | New | +$14.1M |
|
23
TG Therapeutics
TGTX
$4.65B
| $13.6M | 0.86% | 696,390 +421,085 | +153% | +$8.2M |
|
24
Insmed
INSM
$28.8B
| $13.3M | 0.84% | +483,967 | New | +$13.3M |
|
25
Puma Biotechnology
PBYI
$254M
| $12.5M | 0.79% | 1,197,630 +559,604 | +88% | +$5.84M |
|